Pneumocystis pneumonia in patient with lung adenocarcinoma: early side effects from pembrolizumab

Abstract

Immune check point inhibitor has made far-reaching changes in the management of lung adenocarcinoma improving drastically the prognosis. We present a case of a 50 years old women beneficiary of pembrolizumab who has suffered an acute pneumonitis diagnosed with CT imaging the days following the initiation of the drug. The occurrence of immune-related events such as pneumonitis complicates the use of immunotherapy and requires a well verse radiologist in the matter to diagnosis and helps prevent further aggravation.

Keywords

• Pembrolizumab
• Lung cancer
• Pneumocystis
• CT